ClinicalTrials.gg
TerminatedNCT01675973Updated Dec 6, 2012

A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine

A Phase 1 interventional study of RANEXA in Severe Renal Impairment, sponsored by Gilead Sciences. Terminated at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-12-06.

Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment

Why this study was terminated
Study met stopping criteria specified within protocol.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
4
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 553 studies in Renal Insufficiency with a site in United States — 40 open to participants now, 57 under way, 3 of them phase 3. Renal Insufficiency · United States.

Enrollment
448th of 468
4 · median 32
Started
2012
with 22 others
Phase 1
232 of 553
14 open now
Registered
222nd of 553
by date

Among the 553 studies in Renal Insufficiency with a site in United States, this one is the 448th largest by enrollment of the 468 interventional ones that give a count, is one of 23 that started in 2012, is one of 232 in phase 1, and was the 222nd registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

40 of the 553 studies in Renal Insufficiency with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 553 studies in Renal Insufficiency with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the effect of severe renal impairment on the steady-state PK, as well as safety and tolerability, of ranolazine, compared to subjects with normal renal function.

Read the detailed description

The primary objective of this study is to assess the effects of severe renal impairment (RI) on the steady-state pharmacokinetics (PK) of ranolazine and key metabolites. The secondary objective of this study is to assess the safety and tolerability of multiple oral doses of ranolazine in subjects with severe RI.

03

Conditions studied

  • Severe Renal Impairment

Browse trials for

Keywords

  • Ranolazine
  • renal impairment
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion criteria (All Cohorts):

  • Males and females, 18 to 75 years old, inclusive
  • (BMI) 18 to 40 kg/m2, inclusive, at Screening
  • Females of must have a negative pregnancy test at Screening and on Day -1 (Cohort A) or Day -6 (Cohort B) and must agree to use highly effective methods from Screening throughout the duration of the Treatment Period and for 14 days following the last dose of study drug

Inclusion criteria (Cohort A [Healthy subjects with normal renal function] only):

  • Estimated (CLCR), according to the Cockcroft-Gault (C-G) equation, ≥ 90 mL/min at Screening
  • Age, BMI, and sex comparable to those of subjects of Cohort B
  • Good health status as determined by no deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations

Inclusion criteria (Cohort B, Severe RI):

  • Diagnosis of CKD
  • Estimated (eGFR), according to the Modification of Diet in Renal Disease (MDRD) equation, \< 30 mL/min/1.73 m2 (and not receiving dialysis)
  • Stable medication dose and dosing regimen for treatment of the complications of renal disease or other concomitant chronic illnesses for at least 2 weeks prior to study drug administration

Exclusion Criteria:

Exclusion criteria (All Cohorts):

  • History of uncontrolled or unstable cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematopoietic, psychiatric, and/or neurological disease
  • Current or recent (within 3 months) gastrointestinal (GI) disease or any GI surgery that could impact absorption of study drug
  • Any major surgery within 4 weeks of dosing with study drug
  • Donation of blood or plasma to a blood bank or in a clinical study (except a screening visit) within 4 weeks of dosing with study drug
  • Blood transfusion within 4 weeks of dosing with study drug
  • Consumption of > 14 alcoholic drinks per week, or more than 4 alcoholic drinks on any one day
  • History of regular use of tobacco- or nicotine-containing products in excess of 10 cigarettes per day or equivalent
  • History of substance abuse within 12 months prior to Screening
  • Positive drug screen
  • Positive alcohol test
  • Clinically significant history of hepatic disease
  • interval > 480 msec at Screening or Day -6 (for Cohort B) or Day -1 (for Cohort A)
  • History of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmia, or torsade de pointes
  • Known or previous intolerance to ranolazine or any of its
  • Treatment with selected medications
  • Pregnancy or lactation
  • Other condition(s) that, in the opinion of the Investigator, would prevent compliance with the study protocol

Exclusion criteria (Cohort A [Healthy subjects with normal renal function] only):

  • Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, , or clinical laboratory determinations
  • \< 12 g/dL for males, \< 11 g/dL for females at Screening
  • Any prescription and over-the-counter medications, including herbal products

Exclusion criteria (Cohort B, Severe RI):

  • Any clinical, ECG, and laboratory findings beyond those which are consistent with the degree of renal dysfunction
  • History of or anticipated near-term need for renal transplant (within 3 months)
  • History of hemodialysis or peritoneal dialysis within 1 year prior to Screening, or anticipated need for hemodialysis or peritoneal dialysis during the study
  • History of acute renal failure or nephrotic syndrome within 1 year prior to Screening
  • History of diabetic ketoacidosis
  • History of severe hypoglycemia
  • Other condition(s) that, in the opinion of the Investigator, would prevent compliance with the study protocol
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Subjects with severe renal impairment

    Cohort B (subjects with severe RI): Approximately 10 subjects will be enrolled to obtain approximately 8 evaluable subjects.

    Drug: RANEXA

  • Experimental
    Subjects with normal renal function

    Cohort A (healthy subjects with normal renal function): Approximately 10 subjects will be enrolled to obtain approximately 8 evaluable subjects.

    Drug: RANEXA

Interventions

  • DrugRANEXA

    500mg BID up to 1000mg BID

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration vs time curve over the dosing interval at steady state (AUCtau) and Maximum observed plasma concentration at steady-state (Cmax)

    * Maximum observed plasma ranolazine concentration at steady-state (Cmax) \[Time frame: 0, 1, 2, 3, 4, 6, 8, 10, and 12 hours post-dose on Day 7 for Cohort A and Days -1 and 7 for Cohort B\] * Area under the plasma ranolazine concentration versus time curve over the dosing interval at steady state (AUCtau) \[Time frame: 0, 1, 2, 3, 4, 6, 8, 10, and 12 hours post-dose on Day 7 for Cohort A and Days -1 and 7 for Cohort B\]

    Time frame: Day 7 for Cohorts A & B, and Day -1 for Cohort B only.

Secondary outcomes

  1. Number of subjects with AEs

    Time frame: From Day -5 for Cohort B or Day 1 for Cohort A through the 14-day follow-up.

07

Study locations

1 site
  • Clinical Pharmacology of Miami
    Miami, Florida 33014, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2012
First posted
Aug 30, 2012
Start
Jul 2012
Primary completionActual
Aug 2012
CompletionActual
Aug 2012
Last update
Dec 6, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01675973
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Aug 30, 2012
Start date
Jul 2012
Primary completion
Aug 2012
Completion
Aug 2012
Last update
Dec 6, 2012
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranolazine

Start the discussion